HUE039750T2 - Hidroxi-buspiron mozgászavarok kezelésére - Google Patents
Hidroxi-buspiron mozgászavarok kezeléséreInfo
- Publication number
- HUE039750T2 HUE039750T2 HUE15744478A HUE15744478A HUE039750T2 HU E039750 T2 HUE039750 T2 HU E039750T2 HU E15744478 A HUE15744478 A HU E15744478A HU E15744478 A HUE15744478 A HU E15744478A HU E039750 T2 HUE039750 T2 HU E039750T2
- Authority
- HU
- Hungary
- Prior art keywords
- hydroxybuspirone
- treatment
- movement disorders
- disorders
- movement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201470388 | 2014-06-26 | ||
DKPA201470389 | 2014-06-26 | ||
DKPA201570102 | 2015-02-26 | ||
DKPA201570101 | 2015-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE039750T2 true HUE039750T2 (hu) | 2019-02-28 |
Family
ID=53761914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15744478A HUE039750T2 (hu) | 2014-06-26 | 2015-06-25 | Hidroxi-buspiron mozgászavarok kezelésére |
Country Status (13)
Country | Link |
---|---|
US (1) | US11478476B2 (hu) |
EP (1) | EP3160464B1 (hu) |
JP (1) | JP6634445B2 (hu) |
KR (2) | KR20170021848A (hu) |
CN (1) | CN107635555B (hu) |
AU (1) | AU2015281448B2 (hu) |
CA (1) | CA2950469C (hu) |
DK (1) | DK3160464T3 (hu) |
ES (1) | ES2686529T3 (hu) |
HU (1) | HUE039750T2 (hu) |
PL (1) | PL3160464T3 (hu) |
PT (1) | PT3160464T (hu) |
WO (1) | WO2015197079A1 (hu) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3067688A1 (en) * | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use |
EP3661500A1 (en) * | 2017-07-31 | 2020-06-10 | Novartis AG | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
JP7620694B2 (ja) | 2020-07-17 | 2025-01-23 | ノバルティス アーゲー | オピオイド使用の低減用医薬品及びオピオイド禁断の促進用医薬品 |
JP2024521959A (ja) * | 2021-06-09 | 2024-06-04 | プロニラス コーポレイション | オピエート離脱又はオピエート再発に関連する状態を治療又は予防する方法 |
CN113341026A (zh) * | 2021-07-02 | 2021-09-03 | 北京和合医学诊断技术股份有限公司 | Lc_ms_ms检测丁螺环酮及其代谢产物的方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4438119A (en) * | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
WO1993013766A1 (en) * | 1992-01-07 | 1993-07-22 | Merrell Dow Pharmaceuticals Inc. | Treatment of involuntary movements with 5ht1a receptor agonists |
US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
EP1047436B1 (en) * | 1998-01-13 | 2009-10-21 | Synchroneuron, LLC | N-acetylhomotaurinates for use in treating hyperkinesias |
US6150365A (en) * | 1999-08-05 | 2000-11-21 | Bristol-Myers Squibb Company | Anxiety method |
US20050137206A1 (en) | 1999-08-05 | 2005-06-23 | Yevich Joseph P. | Method for treatment of anxiety and depression |
US6593331B2 (en) | 2001-04-17 | 2003-07-15 | Laboratories Upsa | Method for treatment of pain |
US6686361B2 (en) * | 2001-07-24 | 2004-02-03 | Bristol-Myers Squibb Company | R-6-hydroxy-buspirone |
US6821976B2 (en) * | 2001-07-24 | 2004-11-23 | Bristol-Myers Squibb Company | S-6-hydroxy-buspirone |
PL2298766T3 (pl) | 2005-03-03 | 2014-09-30 | H Lundbeck As | Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny |
CN101318020B (zh) * | 2007-06-06 | 2011-09-28 | 四川科瑞德制药有限公司 | 抗焦虑或/和抗抑郁的药物组合物及用途 |
US20110183995A1 (en) | 2008-06-24 | 2011-07-28 | Neurosearch A/S | Eltoprazine for suppression of l-dopa induced dyskinesias |
WO2011026890A1 (en) | 2009-09-07 | 2011-03-10 | Neurosearch A/S | 2, 3, 6 -triamino substituted pyridines as kv7 (kcnq) channel modulators |
KR101825972B1 (ko) * | 2010-10-15 | 2018-02-06 | 콘테라 파르마 에이피에스 | 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합 |
MY169068A (en) | 2012-04-18 | 2019-02-12 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
-
2015
- 2015-06-25 CA CA2950469A patent/CA2950469C/en active Active
- 2015-06-25 DK DK15744478.7T patent/DK3160464T3/en active
- 2015-06-25 EP EP15744478.7A patent/EP3160464B1/en active Active
- 2015-06-25 PT PT15744478T patent/PT3160464T/pt unknown
- 2015-06-25 HU HUE15744478A patent/HUE039750T2/hu unknown
- 2015-06-25 CN CN201580034021.8A patent/CN107635555B/zh active Active
- 2015-06-25 JP JP2017519784A patent/JP6634445B2/ja active Active
- 2015-06-25 US US15/318,518 patent/US11478476B2/en active Active
- 2015-06-25 WO PCT/DK2015/050186 patent/WO2015197079A1/en active Application Filing
- 2015-06-25 AU AU2015281448A patent/AU2015281448B2/en active Active
- 2015-06-25 ES ES15744478.7T patent/ES2686529T3/es active Active
- 2015-06-25 KR KR1020177001613A patent/KR20170021848A/ko not_active Ceased
- 2015-06-25 KR KR1020237008600A patent/KR102527805B1/ko active Active
- 2015-06-25 PL PL15744478T patent/PL3160464T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
PT3160464T (pt) | 2018-10-12 |
CN107635555B (zh) | 2021-02-26 |
EP3160464A1 (en) | 2017-05-03 |
KR20170021848A (ko) | 2017-02-28 |
EP3160464B1 (en) | 2018-07-18 |
KR102527805B1 (ko) | 2023-04-28 |
AU2015281448B2 (en) | 2020-04-09 |
US11478476B2 (en) | 2022-10-25 |
CA2950469A1 (en) | 2015-12-30 |
US20170128446A1 (en) | 2017-05-11 |
JP2017519827A (ja) | 2017-07-20 |
ES2686529T3 (es) | 2018-10-18 |
JP6634445B2 (ja) | 2020-01-22 |
CA2950469C (en) | 2022-09-20 |
DK3160464T3 (en) | 2018-10-29 |
KR20230042131A (ko) | 2023-03-27 |
CN107635555A (zh) | 2018-01-26 |
AU2015281448A1 (en) | 2017-01-05 |
WO2015197079A1 (en) | 2015-12-30 |
PL3160464T3 (pl) | 2018-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283086A (en) | Use of cannabidiol in the treatment of multiple sclerosis complex | |
IL251529A0 (en) | Use of cannabinoids in the treatment of epilepsy | |
IL247841A0 (en) | Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma | |
PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
HK1232147A1 (zh) | 用於治療纖維化的賽尼克韋羅 | |
GB201403093D0 (en) | Therapeutic compounds and their use | |
IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumors | |
IL247589A0 (en) | Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders | |
IL251904A0 (en) | Epilimod for use in the treatment of melanoma | |
PL3160464T3 (pl) | 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych | |
IL246855A0 (en) | Materials for use in the treatment of retinitis | |
IL251840A0 (en) | Use of femiroplast in the treatment of severe asthma | |
EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
IL252043B (en) | A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders | |
ZA201408464B (en) | Composition for the use in treatment of asthma | |
GB201415302D0 (en) | New therapeutic use | |
GB201417719D0 (en) | New treatment | |
GB201410387D0 (en) | Compounds and their therapeutic use | |
GB201408384D0 (en) | New treatment | |
GB201403496D0 (en) | Compounds and their therapeutic use |